Session Date:
Tuesday June 29, 2021
4:00 – 5:00 pm EST
Session Description:
Clinical trials help answer specific questions about new therapies or new ways to use known therapies. For lymphoma patients, clinical trials can provide access to new treatments that are not otherwise available in Canada, test the combination of existing treatments, or provide new treatment options in different settings (i.e. frontline or relapse/refractory). Clinical trials have rigorous and extensive designs to ensure that they are both safe and effective for patients.
There are many active clinical trials in Canada. It is important for lymphoma patients to learn about the Canadian clinical trial landscape to determine whether a new treatment could be available to them. These are important discussions to have with a doctor.
In this presentation, Dr. Neil Berinstein, a principal investigator and site lead for many lymphoma trials, will provide background information about clinical trials, what to expect when enrolled in a trial, how to learn more about clinical trials and treatment options, and important details on the current clinical trial landscape in Canada.
Speaker:
Dr. Neil Berinstein, MD, FRCPC, ABIM
Hematologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
Professor, Department of Medicine, Immunology and Medical Biophysics, University of Toronto
Speaker Biography: Dr. Neil Berinstein is a Professor of Medicine at the University of Toronto and a practicing Hematologist at the Odette-Sunnybrook Cancer Centre in Toronto, Canada. He has held numerous leadership positions in the field of oncology including Head of the Hematology Site group and founding Director of the Advanced Therapeutics Program at the Odette-Sunnybrook Cancer Centre, was the Program Head for the Cancer Vaccine Program at Sanofi Pasteur, and most recently has joined the Ontario Institute for Cancer Research. Dr. Berinstein has a longstanding interest in cancer immunotherapy and continues to develop novel clinical strategies to augment anti-tumour immune responses to cancers. He has specific research interests in using genomic information to develop combination immunotherapy treatment approaches. He has a long track record in immunology and immunotherapy research, being a principal investigator and site lead for many lymphoma trials, and has published approximately 100 manuscripts in scientific and clinical journals.
